Completed PHASE4 INTERVENTIONAL 1-arm NCT01896284

Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor (MACBETH)

Phase IV Study to Evaluate the Efficacy of Aflibercept in Subjects With Neovascular Age-related Macular Degeneration (wAMD), Without Optimal Response to Repeated Monthly Intravitreal Injections of Anti Vascular Endothelial Growth Factor (Anti VEGF-A) Therapy.

Sponsor: Barcelona Macula Foundation

Conditions Wet Macular Degeneration

Interventions 0.5mg aflibercept

Updated 6 times since 2017 Last updated: Nov 21, 2018 Started: Jul 31, 2013 Primary completion: Nov 30, 2014 Completion: Jun 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01896284, this PHASE4 trial focuses on Wet Macular Degeneration and remains completed. Sponsored by Barcelona Macula Foundation, it has been updated 6 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Dec 2018 — Jan 2021 [monthly]

Completed PHASE4

Status: Unknown Status → Completed
Jun 2018 — Dec 2018 [monthly]

Unknown Status PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

First recorded

Jul 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Barcelona Macula Foundation
Bayer
TFS Trial Form Support

Data source: Barcelona Macula Foundation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Barcelona, Spain